Good Life Advisors LLC Sells 1,433 Shares of Stryker Corporation (NYSE:SYK)

Good Life Advisors LLC lowered its stake in Stryker Corporation (NYSE:SYK - Free Report) by 38.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,331 shares of the medical technology company's stock after selling 1,433 shares during the quarter. Good Life Advisors LLC's holdings in Stryker were worth $868,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. J. W. Coons Advisors LLC grew its position in Stryker by 0.7% in the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after buying an additional 26 shares during the last quarter. Mascoma Wealth Management LLC boosted its position in shares of Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after purchasing an additional 27 shares during the period. Lindbrook Capital LLC increased its stake in Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after purchasing an additional 28 shares in the last quarter. JFS Wealth Advisors LLC lifted its stake in Stryker by 4.4% during the fourth quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock valued at $247,000 after buying an additional 29 shares in the last quarter. Finally, Capital & Planning LLC increased its position in shares of Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock worth $304,000 after acquiring an additional 29 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

Shares of SYK traded up $2.18 during trading hours on Friday, reaching $375.44. 1,859,947 shares of the company traded hands, compared to its average volume of 1,336,274. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. The stock's fifty day moving average is $374.45 and its 200 day moving average is $375.41. Stryker Corporation has a 1-year low of $314.93 and a 1-year high of $406.19. The stock has a market cap of $143.30 billion, a P/E ratio of 50.73, a price-to-earnings-growth ratio of 2.81 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.50 earnings per share. Equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SYK shares. Needham & Company LLC reissued a "buy" rating and set a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Truist Financial increased their price objective on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research note on Monday, May 5th. Evercore ISI lowered their target price on Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. BTIG Research set a $403.00 price target on shares of Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Finally, The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $427.30.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.90% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.